Safety and efficacy of reduced intensity myeloablative conditioning regimen with fludarabine, cytarabine arabinoside, and cyclophosphamide for hematological malignancies

Not Applicable

Recruiting

• Conditions: Acute myeloid leukemia(AML), Myelodysplastic syndrome(MDS), Acute lymphoblastic leukemia(ALL), Malignant lymphoma(ML), chronic myeloid leukemia(CML)

• Registration Number: JPRN-UMIN000007281
• Lead Sponsor: Gifu University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-02-13
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with HIV 2) Patients who received gemtuzumab ozogamicin within 3 months 3) Patients with another active malignancy 4) Patients with severe mental disease 5) Patients with severe central nervous system (CNS) lesions (except for CNS lesions of the underlying disease) 6) Patients with active infection 7) Patients who have history of chemotherapy within 21 days before transplantation (except hydroxyurea, cytarabine, or etoposide therapy for blast control) 8) Patients who have hypersensitivity to drugs included in this protocol 9) Patients who are judged inappropriate for the entry into the study by the principle doctor.

Study & Design

• Study Type: Interventional
• Study Design: Not specified